Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs Glimepiride on Urinary Albumin in T2DM
NCT03983551Phase 4Completed
- Sponsor
- Changhua Christian Hospital
- Start
- Mar 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Changhua Christian Hospital. Primary endpoint: Urinary albumin-to-creatinine ratio at 24 weeks. Started Mar 2016; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03983551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983551.